Researchers at Gladstone Institutes reported that two cellular genes act as 'locks' keeping HIV reservoirs dormant and that metformin can activate one of those mechanisms, delaying viral rebound after antiretroviral therapy (ART) interruption in some individuals. The multiomic study in Immunity analyzed ART‑interruption cohorts to identify cell‑intrinsic and extrinsic mechanisms tied to post‑treatment control. Investigators suggest metformin, an inexpensive and widely used diabetes drug, could be advanced into preclinical and clinical studies to test whether it can safely extend remission off ART for subsets of people with HIV.